A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastorna multiforme (GBM).

被引：0
|
作者：
Nguyen, T. D. [1 ]
Lassman, A. B. [1 ]
Lis, E. [1 ]
Rosen, N. [1 ]
Shaffer, D. R. [1 ]
Scher, H. I. [1 ]
Deangelis, L. M. [1 ]
Abrey, L. E. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：59S / 59S
页数：1
相关论文
共 25 条
  • [1] A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM)
    Nguyen, Teri D.
    Lassman, Andrew B.
    Lis, Eric
    Rosen, Neal
    Shaffer, David R.
    Scher, Howard I.
    DeAngelis, Lisa M.
    Abrey, Lauren E.
    [J]. NEURO-ONCOLOGY, 2006, 8 (04) : 447 - 448
  • [2] A phase I/II trial to assess tolerability and efficacy of RAD-001 with gefitinib in patients with glioblastoma multiforme and castrate metastatic prostate cancer
    Shaffer, D. R.
    Abrey, L.
    Beekman, K.
    Morris, M.
    Eicher, C.
    Kelly, W. K.
    Slovin, S.
    Solit, D.
    Rosen, N.
    Scher, H. I.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 419 - 419
  • [3] A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
    Kreisl, Teri N.
    Lassman, Andrew B.
    Mischel, Paul S.
    Rosen, Neal
    Scher, Howard I.
    Teruya-Feldstein, Julie
    Shaffer, David
    Lis, Eric
    Abrey, Lauren E.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2009, 92 (01) : 99 - 105
  • [4] A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
    Teri N. Kreisl
    Andrew B. Lassman
    Paul S. Mischel
    Neal Rosen
    Howard I. Scher
    Julie Teruya-Feldstein
    David Shaffer
    Eric Lis
    Lauren E. Abrey
    [J]. Journal of Neuro-Oncology, 2009, 92 : 99 - 105
  • [5] EFFICACY AND TOLERABILITY OF BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
    Francini, E.
    Mazzaroppi, S.
    Salvati, M.
    Caponnetto, S.
    Laera, L.
    Migali, C.
    Bianco, V.
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [6] Phase I study of gefitinib and rapamycin in adult patients with recurrent glioblastoma multiforme (GBM).
    Phuphanich, Surasak
    Chu, Ray
    Yu, John S.
    Black, Keith L.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3462S - 3462S
  • [7] A phase I study of temozolomide (TMZ) and RAD001 in patients (pts) with glioblastoma multiforme (GBM)
    Mason, W. P.
    MacNeil, M.
    Easaw, J.
    McIntosh, L.
    Lwin, Z.
    Chen, E.
    Eisenhauer, E. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM)
    Trani, L.
    Alam, S. M.
    Rudman, S. M.
    Molife, L. R.
    Middleton, G. W.
    Propper, D.
    Stopfer, P.
    Uttenreuther-Fischer, M. M.
    Wallenstein, G.
    Spicer, J. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Efficacy and tolerability of the novel mTOR antagonist Everolimus (RAD001) in treatment of patients with advanced chronic GcHD after allogeneic stem cell transplantation
    von Harsdorf, S.
    Schmitt, M.
    Ringhoffer, M.
    Schlenk, R.
    Doehner, H.
    Wiesneth, M.
    Bunjes, D.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S106 - S106
  • [10] A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)
    Slomovitz, B. M.
    Lu, K. H.
    Johnston, T.
    Munsell, M.
    Ramondetta, L. M.
    Broaddus, R. R.
    Coleman, R. L.
    Walker, C.
    Gershenson, D. M.
    Burke, T. W.
    Wolf, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
123